By Norma Erickson What happens when a potential blockbuster vaccine (Gardasil, Cervarix, or Gardasil 9) is simply not accepted by the public on the same level as other recommended vaccines? Do the manufacturers and international health authorities re-examine the product to assess whether or not public concerns are valid? Not often, and when they do […]